

(51) International Patent Classification:
G06F 17/27 (2006.01)(21) International Application Number:
PCT/US2013/072691(22) International Filing Date:
2 December 2013 (02.12.2013)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
61/732,024 30 November 2012 (30.11.2012) US
61/772,979 5 March 2013 (05.03.2013) US(71) Applicant: **APPLIED PROTEOMICS, INC.** [US/US];
3545 John Hopkins Court, Suite 150, San Diego, CA
92121 (US).(72) Inventors: **BLUME, John**; 2560 Lake Whatcom
Boulevard, Bellingham, WA 98229 (US). **BENZ, Ryan**;18797 Ambrose Lane, Huntington Beach, CA 92648 (US).
CRONER, Lisa; 11704 Ramsdell Court, San Diego, CA
92131 (US). **DILLON, Roslyn**; 1243 Windsor Road,
Cardiff, CA 92007 (US). **RANDALL, Arlo**; 8 Calle Al-
meja, San Clemente, CA 92673 (US). **JONES, Jeffrey**;
3755 Lockerbie Lane, Glendale, CA 92108 (US). **SKOR,**
Heather; 3799 Ibis Street, San Diego, CA 92103 (US).
STOCKFISCH, Tom; 2336 Canyon Road, Escondido,
CA 92025 (US). **WILCOX, Bruce**; 430 Ohio Avenue,
Harrisonburg, VA 22801 (US). **RUDERMAN, Daniel**;
3765 Effingham Place, Los Angeles, CA 90027 (US).(74) Agents: **HARRADINE, Kelly** et al.; Wilson Sonsini
Goodrich & Rosati, Paten Agent, 650 Page Mill Road,
Palo Alto, CA 94304-1050 (US).(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY,
BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM,
DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT,

[Continued on next page]

(54) Title: METHOD FOR EVALUATION OF PRESENCE OF OR RISK OF COLON TUMORS




FIG. 10

(57) Abstract: The disclosed methods are used to predict or assess colon tumor status in a patient. They can be used to determine nature of tumor, recurrence, or patient response to treatments. Some embodiments of the methods include generating a report for clinical management. The methodology provided herein is intended to detect technical variations and to allow for data normalization and enhance signal detection and build predictive proteins profiles of disease status and response.



HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ,

TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

- *without international search report and to be republished upon receipt of that report (Rule 48.2(g))*
- *with sequence listing part of description (Rule 5.2(a))*